西他沙星

English Name: Sitafloxacin

English alias: DU-6859a; Gracevit < <; 7 - ((S) - ((S) - 7 - Amino - 5 - Azaspiro [2.4] heptan - 5 - yl) - 8 - chloro - 6 - Fluoro - 1 - ((1R, 2S) - 2 - fluorocyclopropyl) - 4 - oxo - 1, 4 - dihydroquinoline - 3 - carboxylic acid; 7 - [(4S) - 4 - 4 - Amino - 6 - azo [2.4] heptan - 6 - yl] - 6 - Fluoro - 1 - ((1R, 2S) - 2 - fluorocyclopropyl) - 2 - fluorocyclopropyl) - 4 - oxo - 1, 4 - oxo - 1, 4 - dihydroquinoline[(2S) -2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic ACI D; 7-[(7S) - 7-amino-5-azaspiro [2.4] heptan-5-yl]-8-chloro-6-fluoro-1-[(2S) -2-fluorocyclopropyl]-4-oxoquinoline-3-carboxylic acid;

CAS: 127254-12-0

Molecular formula: C19H18ClF2N3O3

Molecular weight: 409.81400

Precise quality: 409.10000

PSA:88.56000

LogP:3.46790

Sitafloxacin (INN; also called DU-6859a) is a fluoroquinolone antibiotic that shows promise in the treatment of Buruli ulcer. The molecule was identified by Daiichi Sankyo Co., which brought ofloxacin and levofloxacin to the market. Sitafloxacin is currently marketed in Japan by Daiichi Sankyo under the tradename Gracevit.